FLULIEVA 10 mg contains Fludarabine Phosphate, a purine nucleoside analogue antimetabolite. Inside the cell, it is converted to the active metabolite fludarabine triphosphate, which inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, leading to inhibition of DNA synthesis and apoptosis. It is primarily used in hematological malignancies.

Fludarabine Phosphate is indicated for:

1. Chronic Lymphocytic Leukemia (CLL)
   – Especially relapsed or refractory disease

2. Indolent Non-Hodgkin’s Lymphoma

3. Hairy Cell Leukemia (off-label)

4. Conditioning regimens for stem cell transplantation

Common side effects:

•  Severe myelosuppression (neutropenia, thrombocytopenia, anemia)

•  Nausea, vomiting

•  Fatigue

•  Fever

Serious side effects:

•  Severe immunosuppression → opportunistic infections

•  Neurotoxicity (confusion, seizures at high doses)

•  Autoimmune hemolytic anemia

Monitor CBC, watch for infections; PJP prophylaxis is often required.

Dosage is based on body surface area (BSA).

Typical dosing:

•  25 mg/m²/day IV for 5 consecutive days

•  Repeated every 28 days

10 mg vial allows flexible dosing and pediatric use.

NOTE: This medicine should be taken only under a doctor’s supervision.